These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16862397)

  • 1. Compliance with drug therapy for postmenopausal osteoporosis.
    Weycker D; Macarios D; Edelsberg J; Oster G
    Osteoporos Int; 2006; 17(11):1645-52. PubMed ID: 16862397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.
    Recker RR; Gallagher R; MacCosbe PE
    Mayo Clin Proc; 2005 Jul; 80(7):856-61. PubMed ID: 16007889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with osteoporosis drug therapy and risk of fracture.
    Weycker D; Macarios D; Edelsberg J; Oster G
    Osteoporos Int; 2007 Mar; 18(3):271-7. PubMed ID: 17021945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
    Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J;
    Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT; Safi W; Trinh H
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
    Cramer JA; Gold DT; Silverman SL; Lewiecki EM
    Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
    Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].
    Bartl R; Götte S; Hadji P; Hammerschmidt T
    Dtsch Med Wochenschr; 2006 Jun; 131(22):1257-62. PubMed ID: 16755420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
    Reginster JY
    Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
    Rabenda V; Mertens R; Fabri V; Vanoverloop J; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases.
    Brankin E; Walker M; Lynch N; Aspray T; Lis Y; Cowell W
    Curr Med Res Opin; 2006 Jul; 22(7):1249-56. PubMed ID: 16834823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
    Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG
    Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
    Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
    Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
    Cadarette SM; Solomon DH; Katz JN; Patrick AR; Brookhart MA
    Osteoporos Int; 2011 Mar; 22(3):943-54. PubMed ID: 20532481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.